{"pub": "investingcom", "url": "https://ca.investing.com/news/stock-market-news/briefzai-lab-announces-phase-3-prima-trial-of-zejulaniraparib-1977651", "downloaded_at": "2019-09-29 23:36:05.928668+00:00", "title": "BRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib)", "language": "en", "text": "BRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib)\n\nStock Markets 5 hours ago (Sep 29, 2019 14:31)\n\n\u00a9 Reuters. BRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib) Sept 29 (Reuters) - Zai Lab Ltd : * PHASE 3 PRIMA TRIAL OF ZEJULA\u00ae (NIRAPARIB) IS THE FIRST STUDY TO SHOW A PARP INHIBITOR SIGNIFICANTLY IMPROVES PFS, REGARDLESS OF BIOMARKER STATUS, WHEN GIVEN AS MONOTHERAPY IN WOMEN WITH FIRST-LINE PLATINUM RESPONSIVE ADVANCED OVARIAN CANCER * ZAI LAB- PRIMA STUDY SHOWS NIRAPARIB TREATMENT RESULTED IN 38% REDUCTION IN RISK OF DISEASE PROGRESSION OR DEATH IN STUDY POPULATION COMPARED TO PLACEBO * SAFETY PROFILE DEMONSTRATED IN PRIMA DID NOT DIFFER FROM ESTABLISHED SAFETY PROFILE\n\nBRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib)", "description": "BRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib)", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXNPEB65083_L.jpg", "published_at": "2019-09-29"}